JAZZ
Jazz Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · IE
$213.02
+2.50%Year over year
Reported trailing growth
- Revenue
- +12.6%
- EBITDA
- +266.8%
- EBIT
- +590.5%
- EPS
- +330.3%
- Free cash flow
- +21.9%
- Operating cash flow
- +26.2%
Forward estimates
Based on analyst estimates
- Revenue
- +7.2%
- EBITDA
- +78.6%
- EPS
- +65.4%
Three-year CAGR
- Revenue
- +5.3%
- EBITDA
- -43.7%
- EBIT
- -37.7%
- Net income
- —
- EPS
- —
- Free cash flow
- +14.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026